Accustem Sciences, Inc
14-15 Conduit Street
London, W1S 2XJ
Useful Links
Accustem Sciences, Inc © 2024
Accustem Sciences, Inc
14-15 Conduit Street
London, W1S 2XJ
Accustem Sciences, Inc © 2024
Keeren Shah
Chief Finance Officer
Keeren has held a variety of leadership roles in Finance over the last 20 years. In addition to serving as AccuStem’s Chief Financial Officer, she also serves as the Chief Financial Officer of OKYO Pharma Ltd, Tiziana Life Sciences, Ltd. and Rasna Therapeutics Inc., having previously served as the Group Financial Controller for all businesses from June 2016 to July 2020. Prior to joining this portfolio of companies, Keeren spent 10 years at Visa, Inc. as a senior leader on its Finance team where she was responsible for key financial controller activities, financial planning and analysis, core processes as well as leading and participating in key transformation programs including Visa Inc.’s initial public offering. Before joining Visa, Keeren also held a variety of finance positions at other leading companies including Arthur Andersen and BBC Worldwide. She holds a Bachelor of arts with honours in Economics and is a member of the Chartered Institute of Management Accountants.
Keeren Shah
Chief Finance Officer
Keeren has held a variety of leadership roles in Finance over the last 20 years. In addition to serving as AccuStem’s Chief Financial Officer, she also serves as the Chief Financial Officer of OKYO Pharma Ltd, Tiziana Life Sciences, Ltd. and Rasna Therapeutics Inc., having previously served as the Group Financial Controller for all businesses from June 2016 to July 2020. Prior to joining this portfolio of companies, Keeren spent 10 years at Visa, Inc. as a senior leader on its Finance team where she was responsible for key financial controller activities, financial planning and analysis, core processes as well as leading and participating in key transformation programs including Visa Inc.’s initial public offering. Before joining Visa, Keeren also held a variety of finance positions at other leading companies including Arthur Andersen and BBC Worldwide. She holds a Bachelor of arts with honours in Economics and is a member of the Chartered Institute of Management Accountants.
Joe Flanagan
Chief Business Officer
Joe has 25 years of sales excellence experience and is one of the most sought after talents in Oncology. He is a strategic expert, playing a leading role in the commercial development and successful launch of several product offerings from early-stage diagnostic start ups to large pharmaceutical companies. Prior to joining Accustem, Joe served as the VP of Sales for Precision Therapeutics as well as the VP of Market Development for Biodesix and Agendia. During his tenure, record revenues were realized as a result of his efforts to enhance the clinical agility and logistical focus of each company’s sales team. Most recently, he led strategic development efforts with Ambry Genetics’ Oncology franchise.
Wendy Blosser
Chief Executive Officer
Wendy brings 25 years of success launching, relaunching and building organizations in diagnostic, surgical and capital sales, with a focus in Oncology and Women’s Health. She has achieved record revenue growth at a variety of organizations from early-stage start ups to Fortune 500 companies. Most recently, Wendy has served as CCO at Agendia, Animated Dynamics and Biodesix. Prior to Biodesix, Wendy served as VP of Sales with Integrated Oncology (LabCorp subsidiary) where she lead the successful integration of Genzyme Genetics following its acquisiton for $925M. Before joining Integrated Oncology, she held several leadership roles with Cytyc Corporation prior to its $6.2B acquisition by Hologic.
Jeff Fensterer
Chief Operating Officer
Jeff has spent the last 20 years with start ups at various organizational stages, leading marketing and product strategy in his most recent roles at Agendia, Animated Dynamics and Biodesix. His scientific expertise and keen commercial perspective enable organizations to take clinical data and translate it into impactful product messaging and publication strategies. His exceptional track record in long-term strategic planning is enhanced by experience in a broad spectrum of roles including marketing, sales, R&D, market access, lab operations, clinical development, business development and IT. Jeff holds a MBA from Carnegie Mellon University.
